Enzene Biosciences Opens $50m US Biomanufacturing Facility
Enzene Biosciences, a subsidiary of Alkem Laboratories, has opened a new $50m biomanufacturing facility in Hopewell, New Jersey, US. The facility, announced in June 2023, spans over 7,430sqm and is Enzene's first major manufacturing investment in the US. Governor Phil Murphy praised the decision to locate the 'news-making' facility in the region.
The new site will initially create 50 jobs, with the number expected to reach 300. The 'EnzeneX 2.0' platform, used in the facility, aims to enhance sustainability, scalability, and efficiency. It achieves ten times the yield of traditional methods and lowers costs to $40 per gram. The facility focuses on fed-batch drug substance manufacturing using this innovative platform.
Under the leadership of CEO Himanshu Gadgil, Enzene has expanded with this biopharma plant in Hopewell, New Jersey. Gadgil provides scientific leadership and drives the company's vision to produce affordable biosimilars for diverse medical conditions. With this new facility, Enzene positions itself as a global continuous manufacturing partner.
The new Enzene Biosciences facility in Hopewell, New Jersey, promises a cost-efficient, high-yield 'breaking news' biomanufacturing solution. It creates jobs and contributes to the region's economy, with initial employment reaching 50 and expected to grow to 300. The 'EnzeneX 2.0' platform's efficiency and low costs are expected to revolutionize biosimilar production.
Read also:
- MRI Scans in Epilepsy Diagnosis: Function and Revealed Findings
- Hematology specialist and anemia treatment: The role of a hematologist in managing anemia conditions
- Trump announces Chinese leader's confirmation of TikTok agreement
- EU Leaders Discuss 'Drone Wall' to Tighten Border Security After Munich Incident
